Blog


Chiara Zambon

Chiara Zambon

Chiara is Vice-President of the board of Zambon Company S.p.A., holding of the Group, member of the Board of Directors of Zambon S.p.A. and of ZaCh – Zambon Chemicals. She is also member of the Strategic Advisory Board of Zambon and followed, as member of the Board of Directors, from its origins in 2003, ZCube the incubator of Zambon Group. From 1989 to 1999 worked...

Read More


Giovanni Rizzo

Giovanni Rizzo

Giovanni is CEO of iDNA Ltd, a consulting firm for drug discovery and early preclinical development, helping start-up for funds raising through access to business investors, venture capital firms and pharmaceutical companies. He is also Honorary Senior Lecturer at University College London (UCL) and Peer Reviewer Expert – European Commission. He was Head of Biology at Intercept Pharmaceuticals (ICPT), a NY-based biotech company, focused on...

Read More


Federica Draghi

Federica Draghi

Federica is a Director at Genextra, she joined in 2006 and since then has been involved in a number of activities ranging from evaluation of new investing opportunities to partnering, licensing as well as strategic development of Genextra’s subsidiary companies. Federica is also Chief Operating Officer of Congenia s.r.l. and member of the Board of Directors of Erydel S.p.A., two of Genextra’s portfolio companies. Before...

Read More


Luca Benatti

Luca Benatti

Luca is CEO of EryDel S.p.A. He has over 25 year experience in Pharma and Biotech. From 1985-1998 he held several positions in Farmitalia, Pharmacia&Upjohn. He was Co-founder, CEO of Newron Pharmaceuticals, until May 2012. Under his guidance, Newron developed a pipeline of innovative therapies, with most advanced compound safinamide approved in EU for the treatment of Parkinson’s disease. During his tenure, Newron raised significant...

Read More


Paolo Fundarò

Paolo Fundarò

Mr. Fundarò has been Genextra’s chief financial officer since its inception in 2004 and he has served as a member of the board of directors of Genextra’s portfolio companies. In particular, he is currently Chairman of Intercept Pharmaceutical and Innovheart, Director of Erydel, Managing Director of Congenia. Before joining Genextra Mr. Fundarò was in charge of finance and strategic planning for Fastweb from 2000 to 2004. Previously,...

Read More